Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/neu-Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial

Journal of the American College of Surgeons

Volumn 210, Issue 2, 2010, Pages 140-147

  Patil, Ritesh ^a   Clifton, Guy T ^b   Holmes, Jarrod P ^c   Amin, Asna ^d   Carmichael, Mark G ^d   Gates, Jeremy D ^b   Benavides, Linda H ^b   Hueman, Matthew T ^d   Ponniah, Sathibalan ^d   Peoples, George E ^b,d  

^a Windber Medical Center   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^d United States Military Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E 75; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; HLA A3 ANTIGEN; PEPTIDE VACCINE; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BONE PAIN; BREAST CANCER; CANCER IMMUNIZATION; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; GENE OVEREXPRESSION; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

BREAST NEOPLASMS; CANCER VACCINES; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HLA-A2 ANTIGEN; HLA-A3 ANTIGEN; HUMANS; MIDDLE AGED; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 74749089482     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2009.10.022     Document Type: Article

References (40)

1. Pritchard K.I., Shepherd L.E., O'Malley F.P., et al. National Cancer Institute of Canada Clinical Trials Group: HER2 and responsiveness of breast cancer to adjuvant therapy. N Engl J Med 354 (2006) 2103-2111
2. Anderson B.W., Peoples G.E., Murray J.L., et al. Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals. Clin Cancer Res 6 (2000) 4192-4200
3. Zaks T.Z., and Rosenberg S.A. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 58 (1998) 4902-4908
4. Knutson K.L., Schiffman K., Cheever M.A., and Disis M.L. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 8 (2002) 1014-1018
5. Murray J.L., Gillogly M.E., Przepiorka D., et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 8 (2002) 3407-3418
6. Madjd Z., Spendlove I., Pinder S.E., et al. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 117 (2005) 248-255
7. Rolland P., Deen S., Scott I., et al. Human leukocyte antigen class I antigen expression is an independent prognosis factor in ovarian cancer. Clin Cancer Res 13 (2007) 3591-3596
8. Watson N.F., Ramage J.M., Madjd Z., et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 118 (2006) 6-10
9. Lee T.D. Distribution of HLA antigens in North American caucasians, North American blacks and orientals. In: Lee J. (Ed). The HLA system (1990), Springer-Verlag, New York 154
10. Alves P.M., Viatte S., Fagerberg T., et al. Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. Cancer Immunol Immunother 56 (2007) 1795-1805
11. Ras E., van der Burg S.H., Zegveld S.T., et al. Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). Hum Immunol 53 (1997) 81-89
12. Zhang H.G., Chen H.S., Peng J.R., et al. Specific CD8(+)T cell responses to HLA-A2 restricted MAGE-A3 p271-279 peptide in hepatocellular carcinoma patients without vaccination. Cancer Immunol Immunother 56 (2007) 1945-1954
13. Dong H.L., Li Z.S., Ye J., et al. Identification of HLA-A2-restricted CTL epitope encoded by the MAGE-n gene of human hepatocellular carcinoma. Cancer Biol Ther 3 (2004) 891-898
14. Lustgarten J., Theobald M., Labadie C., et al. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. Hum Immunol 52 (1997) 109-118
15. Linehan D.C., Goedegebuure P.S., Peoples G.E., et al. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 155 (1995) 4486-4491
16. Peoples G.E., Goedegebuure P.S., Andrews J.V., et al. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol 151 (1993) 5481-5491
17. Darrow T.L., Slingluff C.L., and Seigler H.F. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes: evidence for shared tumor antigens. J Immunol 142 (1989) 3329-3335
18. Kono K., Rongcun Y., Charo J., et al. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 78 (1998) 202-208
19. Gourley C., Thornton C., Massie C., et al. Is there a relationship between HLA type and prognostic factors in breast cancer?. Anticancer Res 23 (2003) 633-638
20. Iaffaioli R.V., Maio M., Ruggiero G., et al. HLA and prognostic factors in primary breast cancer. Int J Cancer 35 (1985) 581-585
21. Gamzatova Z., Villabona L., Dahlgren L., et al. Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol 103 (2006) 145-150
22. Peoples G.E., Holmes J.P., Hueman M.T., et al. Combined clinical trial results of a HER-2/neu (ε{lunate}75) vaccine for the prevention of recurrence in high risk breast cancer patients. United States Military Cancer Institute Clinical Trials Group Study. I-01 and I-02. Clin Cancer Res 14 (2008) 797-803
23. Fisk B., Blevins T.L., Wharton J.T., and Ioannides C.G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181 (1995) 2109-2117
24. Parker K.C., Bednarek M.A., and Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152 (1994) 163-175
25. Rammensee H.G., Bachmann J., and Stevanovic S. MHC ligands and peptide motifs (Molecular Biology Intelligence Unit) (1997), Springer, New York
26. Sotiropoulou P.A., Perez S.A., Iliopoulou E.G., et al. Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu-positive epithelial tumors. Br J Cancer 89 (2003) 1055-1061
27. Hueman M.T., Dehqanzada Z.A., Novak T.E., et al. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin Cancer Res 11 (2005) 7470-7479
28. Woll M.M., Fisher C.M., Ryan G.B., et al. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. J Clin Immunol 24 (2004) 449-461
29. Jordan T.J., Sunderam G., Thomas L., and Reichman L.B. Tuberculin reaction size measurement by the pen method compared to traditional palpation. Chest 92 (1987) 234-236
30. Mittendorf E.A., Holmes J.P., Ponniah S., and Peoples G.E. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother 57 (2008) 1511-1521
31. Cibotti R., Kanellopoulos J.M., Cabaniols J.P., et al. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci USA 89 (1992) 416-420
32. Dols A., Meijer S.L., Smith II J.W., et al. Allogeneic breast cancer cell vaccines. Clin Breast Cancer 3 Suppl 4 (2003) S173-S180
33. Sherman L.A., Burke T.A., and Biggs J.A. Extracellular processing of peptide antigens that bind class I major histocompatibility molecules. J Exp Med 175 (1992) 1221-1226
34. Vitiello A., Potter T.A., and Sherman L.A. The role of beta 2-microglobulin in peptide binding by class I molecules. Science 250 (1990) 1423-1426
35. Mittendorf E.A., Gurney J.M., Storrer C.E., et al. Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer. Surgery 139 (2006) 407-418
36. Slingluff Jr. C.L., Petroni G.R., Chianese-Bullock K.A., et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 13 (2007) 6386-6395
37. Holmes J.P., Amin A., Storrer C.E., et al. Clinical and immunologic effects of a HER2/neu (E75) peptide vaccine booster in previously vaccinated breast cancer patients. [abstract]. J Clin Oncol ASCO Annu Meet Proc 25 (2007) 3014
38. Klarnet J.P., Matis L.A., Kern D.E., et al. Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory. J Immunol 138 (1987) 4012-4017
39. Disis M.L., Grabstein K.H., Sleath P.R., and Cheever M.A. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 5 (1999) 1289-1297
40. Holmes J.P., Benavides L.C., Gates J.D., et al. Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER2/neu peptide (AE37) vaccine. J Clin Oncol 26 (2008) 3426-3433